Peptide calculators

BPC-157

200-500 mcg · 2x daily (morning and evening)

15-amino acid peptide derived from human gastric juice (Sikiric, J Physiol Paris 1993). Studied for tendon, ligament, muscle, and gut repair. Plasma half-life is under an hour in rodent PK (Sikiric, Curr Pharm Des 2010, PMID 20166983); the 2x daily protocol is based on pharmacodynamic effect, not drug persistence. No published human PK.

TB-500

2-5 mg · 2x weekly

Synthetic fragment of thymosin beta-4. Studied for tissue repair, wound healing, and inflammation reduction. No published human PK for the synthetic peptide; the listed half-life is a community estimate from endogenous Tβ4 kinetics (Mora, Ann N Y Acad Sci 2007).

BPC-157 / TB-500

500-1000 mcg · 1x daily during a 4 to 6 week loading phase

Pre-mixed healing blend (often sold as the 'wolverine stack') combining BPC-157 and TB-500 in one vial, usually 50/50 by mass. Doses on this page are the total peptide drawn, so a 500 mcg draw from a 50/50 blend delivers roughly 250 mcg of each. Run on its own, BPC-157 is typically 2x daily (Sikiric, Curr Pharm Des 2010, PMID 20166983) and TB-500 about 2x weekly, so injecting the blend daily front-loads TB-500 relative to a standalone protocol. Neither synthetic peptide has published human PK; the half-lives and the loading-phase schedule are community-derived, not label-based. Studied components target tendon, ligament, muscle, and soft-tissue repair.

Semaglutide

250-2400 mcg · 1x weekly

GLP-1 receptor agonist (94% structural homology to human GLP-1, Lau J Med Chem 2015, PMID 26308095). Reduces appetite and slows gastric emptying. Dosed weekly with gradual titration up from 0.25 mg per the Wegovy label (FDA 2024). STEP 1 trial (Wilding NEJM 2021, PMID 33567185) reported ~14.9% mean weight loss at 68 weeks on 2.4 mg.

Retatrutide

2-12 mg · 1x weekly

Investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly. Phase 2 trial (Jastreboff, NEJM 2023, PMID 37366315) reported up to ~24% mean body weight loss at 12 mg weekly over 48 weeks. Titrate from 2 mg to reduce GI side effects. Phase 3 TRIUMPH program is ongoing.

Tirzepatide

2.5-15 mg · 1x weekly

Dual GIP/GLP-1 receptor agonist. Dosed weekly with titration starting at 2.5 mg per the Mounjaro/Zepbound labels (FDA 2024). SURMOUNT-1 (Jastreboff NEJM 2022, PMID 35658024) reported ~20.9% mean weight loss at 15 mg/72 weeks; SURPASS-2 (Frias NEJM 2021, PMID 34170647) showed stronger glycemic + weight effects vs semaglutide head-to-head.

AOD-9604

250-500 mcg · 1x daily

Modified HGH fragment (amino acids 177-191). Targets fat metabolism without the growth-promoting effects of full HGH; lipolytic activity in adipocytes was shown by Heffernan in rodent models (Endocrinology 2001, PMID 11713213). The Metabolic Pharmaceuticals Phase 2b obesity trial reported in 2007 did not show significant weight loss vs placebo at 1 mg/day, and AOD-9604 has never gained drug approval; clinical efficacy in humans remains unproven.

MOTS-c

5-10 mg · 3-5x weekly

Mitochondria-derived peptide encoded in mtDNA. Studied for metabolic regulation, exercise mimicry, and insulin sensitivity. Human dosing is not established in published trials; the range below reflects community protocols, not clinical data.

Cagrilintide

250-2400 mcg · 1x weekly

Long-acting amylin analog (AM833) from Novo Nordisk, given once weekly by subcutaneous injection with an elimination half-life of 159-195 hours (Enebo 2021, Lancet, PMID 33894838). In a phase 2 monotherapy dose-finding trial, weekly cagrilintide titrated to 4.5 mg produced about 10.8% mean weight loss at 26 weeks versus 3.0% with placebo (Lau 2021, Lancet, PMID 34798060). It is the amylin component of the fixed-dose combination CagriSema (with semaglutide 2.4 mg), which reached 22.7% on-treatment weight loss at 68 weeks in the phase 3 REDEFINE 1 trial (Garvey 2025, NEJM, PMID 40544433). Standalone cagrilintide remains investigational and is not FDA-approved.

Survodutide

600-6000 mcg · 1x weekly

Investigational glucagon receptor / GLP-1 receptor dual agonist (BI 456906) from Boehringer Ingelheim, acylated with a C18 fatty-acid chain for once-weekly dosing (~6-7 day half-life). A phase 2 dose-finding obesity trial (le Roux, Lancet Diabetes Endocrinol 2024, PMID 38330987) reported up to ~18.7% mean weight loss at 4.8 mg weekly over 46 weeks; a phase 2 MASH trial (Sanyal, NEJM 2024, PMID 38847460) showed fibrosis improvement at 2.4-6.0 mg weekly. Titrated up from 0.6 mg to limit GI effects; not FDA/EMA approved (phase 3 SYNCHRONIZE program ongoing).

Mazdutide

3-9 mg · 1x weekly

Investigational GLP-1 receptor / glucagon receptor dual agonist (IBI362), licensed by Innovent from Eli Lilly and acylated for once-weekly dosing. A phase 2 trial in Chinese adults (Ji, Nat Commun 2023, PMID 38092790) reported placebo-adjusted weight loss up to ~12.3% at 6 mg over 24 weeks; phase 3 GLORY-1 (Ji, NEJM 2025, PMID 40421736) reported ~14.3% mean weight loss at 6 mg over 48 weeks. Titrated weekly; approved by China's NMPA (2025) but not FDA/EMA.

Ipamorelin

100-300 mcg · 1-3x daily (fasted AM

Selective ghrelin receptor agonist. Triggers pulsatile growth hormone release without raising cortisol or prolactin (Raun, Eur J Endocrinol 1998, PMID 9849822), which is why it gets paired with CJC-1295 instead of older GHRPs. Human PK reports ~2 h half-life (Gobburu, Pharm Res 1999, PMID 10496658).

CJC-1295 / Ipamorelin

200-300 mcg · 1x daily before bed

GHRH + secretagogue combo. Stimulates pulsatile growth hormone release. The 0.5 h half-life reflects the no-DAC ('Mod GRF 1-29') CJC-1295 component (Frohman, J Clin Invest 1986); Ipamorelin itself runs ~2 h (Gobburu, Pharm Res 1999). The DAC variant of CJC-1295 has a half-life of ~6–8 days but is not in this combo. Studied for GH output, sleep quality, and recovery.

Sermorelin

200-500 mcg · 1x daily before bed

GHRH analog containing the first 29 amino acids of native GHRH. Stimulates natural GH production. Very short serum half-life ~11-12 min (Walker, Clin Interv Aging 2006, PMID 18046908). GH pulse peaks ~15-60 min post-injection, then drops fast.

HGH

200-4000 mcg · 1x daily

Recombinant human growth hormone (somatropin). Adult GH-deficiency replacement is typically 0.2-0.6 mg/day (~0.6-1.8 IU) per AACE 2019 guidelines (Yuen, Endocr Pract 2019, PMID 31760818). Doses above ~2 IU/day are supraphysiologic and used off-label for body composition. WHO IS 98/574 reference standard: 3 IU per mg somatropin, so 1 IU ≈ 333 mcg. Contraindicated in active malignancy, proliferative retinopathy, and acute critical illness (Genotropin USPI §4; Takala, NEJM 1999, PMID 10477776 for ICU mortality signal).

Tesamorelin

1-2 mg · once daily

Tesamorelin (brand Egrifta, Egrifta SV, Egrifta WR; developmental code TH9507) is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release endogenous growth hormone. It is FDA-approved to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy, where a 26-week trial cut visceral adipose tissue by roughly 15% versus a 5% increase on placebo (Falutz 2007, N Engl J Med, PMID 18057338). It is a lyophilized powder reconstituted before once-daily subcutaneous injection, with a very short elimination half-life of about 8-11 minutes and subcutaneous bioavailability under 4% per the Egrifta SV/WR FDA labels (DailyMed 2024).

CJC-1295 (with DAC)

500-2000 mcg · 1-2x weekly

Long-acting GHRH(1-29) analog bearing a Drug Affinity Complex (DAC) that covalently binds serum albumin, extending half-life to ~6-8 days versus minutes for native GHRH. In healthy adults, single subcutaneous doses raised growth hormone and IGF-1 for roughly 6-11 days (Teichman, J Clin Endocrinol Metab 2006, PMID 16352683). Sold as a research chemical with no approved human therapeutic indication and no long-term safety data. Distinct from the shorter-acting modified GRF(1-29)/ipamorelin blend. Weekly research dosing figures are community practice, not label-derived.

GHK-Cu

200-600 mcg · 1x daily

Naturally occurring copper tripeptide. Almost all clinical evidence is topical; subcutaneous dosing is not established in human trials and the SC range below is extrapolated from anecdotal protocols. In cultured fibroblasts, GHK-Cu raised collagen type 1 expression (Maquart/Pickart, FEBS Lett 1988, PMID 3169264). Studied for skin remodeling, wound healing, and hair growth.

PT-141

500-1750 mcg · As needed

Melanocortin receptor agonist studied for sexual dysfunction. Acts on the CNS, not the vascular system. FDA-approved as Vyleesi at 1.75 mg SC for HSDD in premenopausal women (bremelanotide USPI, FDA 2019). Contraindicated in uncontrolled hypertension, known cardiovascular disease, and pregnancy (Vyleesi USPI §4-§5.1, §8.1). Reduces oral naltrexone exposure ~60%; avoid in patients on naltrexone for opioid use disorder (Vyleesi USPI §7.1).

Gonadorelin

100-200 mcg · EOD or 2-3x weekly

Synthetic GnRH decapeptide identical to endogenous gonadotropin-releasing hormone; pulsatile receptor stimulation triggers pituitary LH and FSH release (FDA Factrel label, NDA 017866). Plasma half-life is only ~2-10 minutes. In TRT it is used off-label to help preserve testicular volume and intratesticular testosterone during exogenous-androgen gonadotropin suppression, though no large RCTs support this specific use. Chronic non-pulsatile exposure paradoxically downregulates GnRH receptors and suppresses gonadotropins. Community TRT dosing figures are practice-based, not label-derived.

HCG

250-1500 mcg · 2-3x weekly (EOD)

Human chorionic gonadotropin, an LH-analog glycoprotein hormone that stimulates testicular Leydig cells to produce testosterone. Low-dose HCG (125-500 IU every other day) maintained intratesticular testosterone during testosterone-induced gonadotropin suppression in normal men (Coviello, J Clin Endocrinol Metab 2005, PMID 15713727); it is also used to restore spermatogenesis and fertility in hypogonadotropic hypogonadism. Dosed in international units (IU), not mg. Standard reconstitution is 5000 IU + 2 ml bacteriostatic water = 2500 IU/ml, so 250 IU = 0.1 ml = 10 units on a U-100 insulin syringe.

DSIP

100-300 mcg · 1x daily

Neuropeptide studied for promoting delta-wave sleep. May normalize sleep architecture and speed up sleep onset.

Selank

250-750 mcg · 1-2x daily

Synthetic tuftsin analog. Studied for anxiolytic and nootropic effects. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences). Published clinical work is almost entirely intranasal; the subcutaneous route is not in peer-reviewed trials.

Semax

200-600 mcg · 1-2x daily

Synthetic ACTH(4-10) analog. Studied for cognitive enhancement, neuroprotection, and BDNF upregulation. Developed in Russia. Published clinical work is almost entirely intranasal; the subcutaneous route is not in peer-reviewed trials.